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Antiphospholipid syndrome (APS) is a heterogeneous entity with a wide variation in clinical course and laboratory 
profile. It is accepted that the presence of antiphospholipid antibodies (aPL) confers a higher risk for both thrombosis 
and pregnancy morbidity, but quantifying such a risk is still a challenge. As a consequence, clinicians are unable to 
tailor the treatment according to the risk. 
Recently, Otomo et al 1 developed and validated the so-called ‘antiphospholipid score’ (aPL-S) by testing multiple aPL 
and evaluating the aPL-S efficacy for the diagnosis of APS and predictive value for thrombosis. This score was shown 
to be a useful quantitative index for diagnosing APS and to be valuable as a predictive marker for thrombosis in 
autoimmune diseases. 
In order to independently validate the aPL-S, we applied the proposed score system to a cohort of 211 consecutive 
patients who attended the Louise Coote Lupus Unit (St Thomas Hospital, London, UK). All the patients fulfilled the 
1982 criteria for systemic lupus erythematosus (SLE).2 
Overall, 81 patients fulfilled criteria for APS 3 and 73 patients had a history of thrombosis (48 arterial, 41 venous 
thrombosis). Out of 144 women who had ever been pregnant, 41 had a history of miscarriages and 34 a history of fetal 
death. To validate the aPL-S, we adapted the proposed score using our inhouse cut-off values for aPL testing as 
previously reported or according to the current guidelines, as appropriate.3–8 aPL profile included anticardiolipin 
antibodies, lupus anticoagulant by partial thromboplastin time (aPTT – IL-test APTT-SP, Instrumentation Laboratory, 
Milan, Italy) and dilute Russell viper venom time, anti-β2glycoprotein-I antibody, and antibodies to 
phosphatidylserine–prothrombin complex. 
aPL-S was calculated for each patient by adding together the points corresponding to the risk factors as 
described.1 Higher values of aPL-S were seen in patients who experienced thrombosis and/or pregnancy loss when 
compared with those without clinical events (median 17 (0–86) vs 4 (0–31), p<0.001). When analysing clinical 
subgroups, patients who experienced thrombosis or pregnancy loss showed higher aPL-S compared with those without 
clinical events (median 18 (0–86) vs 4 (0–27), p<0.001 for thrombosis; 7 (0–69) vs 3 (0–29), p=0.029 for pregnancy 
loss) (figure 1). In our cohort, when the cut-off level for the aPL-S was defined as 30, as per the original study by 
Otomo et al,1 the sensitivity and specificity of the aPL-S were 39% and 95%, respectively, compared with 37% and 
96% shown in the Japanese cohort. The positive predictive value of an aPL-S ≥30 was 36%, whereas the negative 
predictive value was 91%. 
 
We demonstrated that the aPL profile can be successfully quantified by the aPL-S in an independent cohort of SLE 
patients. The aPL-S correlated with a history of thrombosis or pregnancy loss in our cohort, suggesting that the aPL-S is 
a suitable quantitative marker of APS. 
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Antiphospholipid score (aPL-S) in systemic lupus erythematosus (SLE). The aPL-S was calculated according to 
Otomo et al.1 Data are shown as box plots, where each box represents the 25th to 75th percentiles: lines inside the box 
represent the median. The whiskers represent the 95% CI. Higher values of aPL-S were seen in patients who 
experienced thrombosis and/or pregnancy loss (PL) when compared with those without clinical events (p<0.001 by 
Mann–Whitney U test). When analysed separately, patients who experienced thrombosis or PL showed higher aPL-S 
when compared with those without clinical events. 
 
